Exicure, Inc.

As of February 9, 2024, Exicure, Inc. is significantly overvalued with a P/B ratio of 10.08 and negative financial metrics, leading to a downgrade in its valuation grade and a year-to-date stock decline of 52.45%, contrasting sharply with its peers and the S&P 500.

As of June 18, 2025, the market trend has shifted to sideways, with mixed technical indicators showing bearish signals on the weekly MACD and RSI, while daily moving averages remain mildly bullish, indicating overall market indecision.

As of March 2022, the management team of Exicure, Inc. includes Timothy Walbert (Independent Chairman), Dr. David Giljohann (CEO and Director), Dr. Chad Mirkin, James Sulat, Dr. Jeffrey Cleland, Bosun Hau, and Helen Kim (all Directors). They oversee the company's strategic direction and operations.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics using its Spherical Nucleic Acid technology for immuno-oncology and genetic disorders, with a market cap of $52.56 million and a recent net profit of -$7 million.

As of Jun 18, Exicure, Inc. has a market capitalization of 52.56 million, with net sales of 0.50 million and a net profit of -9.70 million over the last four quarters. The company reported shareholder's funds of 6.77 million and total assets of 15.06 million as of Dec 24.